SCHEMBL4853429

SCHEMBL4853429

CCc1ccc(C(O)c2ccncc2O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
LMNA P02545 1/20 0.37
RAB9A P51151 4/20 0.37
NPC1 O15118 3/20 0.37
KMT2A Q03164 1/20 0.37
CYP17A1 P05093 3/20 0.37
CYP3A4 P08684 1/20 0.37
CYP19A1 P11511 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
ALDH1A1 P00352 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
ATM Q13315 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5388162 0.82 L3MBTL1 (0.51) SMN1; SMN2L3MBTL1LMNARAB9ANPC1
SCHEMBL4857317 0.80 L3MBTL1 (0.39) IDO1TDO2SMN1; SMN2L3MBTL1LMNA
SCHEMBL19303026 0.77 TSHR (0.48) SMN1; SMN2L3MBTL1LMNARAB9ANPC1
Hydrochloric Acid SCHEMBL4851324 0.76 CA1 (0.47) CYP19A1CYP11B1CYP11B2ALDH1A1MAPK1
Hydrochloric Acid SCHEMBL5385904 0.73 ESR1 (0.47) SMN1; SMN2L3MBTL1LMNARAB9ANPC1
SCHEMBL4859922 0.71 IDO1 (0.33) IDO1TDO2L3MBTL1LMNARAB9A
SCHEMBL4852032 0.70 RAB9A (0.40) SMN1; SMN2RAB9ANPC1KMT2ACYP17A1
SCHEMBL17403394 0.69 TSHR (0.57) SMN1; SMN2LMNARAB9ANPC1KMT2A
SCHEMBL4852017 0.69 RAB9A (0.39) SMN1; SMN2RAB9ANPC1KMT2ACYP17A1
SCHEMBL12291880 0.69 SMN1; SMN2 (0.46) SMN1; SMN2L3MBTL1LMNARAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439232-B2 Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-10-21 US disclosed
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2006-08-31 US disclosed
EP-1609799-A1 HETEROARYL 5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME TAISHO PHARMACEUTICAL CO., LTD (JP) 2005-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same SLC5A2, SLC5A1, UGGT1 IDO1 3665/4885TDO2 1549/4885SMN1; SMN2 4397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.